Bulgarian pharmaceuticals producer Sopharma [BUL:SFA] said on Thursday that its sales revenue fell by 8% on the year in January-November due to lower exports.
The company’s revenue from export sales sank by 14% year-on-year in the eleven months through November, while sales on the domestic market climbed by 4%, Sopharma said in a stock exchange filing.
In November alone, Sopharma recorded a 10% annual decline in sales revenue. The company’s export sales dropped by 17% on the year, while domestic sales remained unchanged.
As of 1348 CET on Thursday, shares in Sopharma traded flat at 5.72 levs ($3.07/2.92 euro) on the Bulgarian Stock Exchange.
